Vertex Pharmaceuticals
May 12, 2011
PDF

Vertex Shareholders Approve Proxy Proposals at Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2011 Annual Meeting of Shareholders.

At the meeting, shareholders re-elected director nominees Matthew W. Emmens and Wayne J. Riley, M.D. and elected nominee Margaret C. McGlynn to the company's board of directors. Their terms will expire at the 2014 Annual Meeting of Shareholders. Ms. McGlynn most recently served as President, Global Vaccines and Infectious Diseases, for Merck & Co., Inc. In her nearly three decades at Merck, Ms. McGlynn held a number of leadership roles focused on marketing, sales and managed care activities for Merck's portfolio of medicines. She is a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences and holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo. The addition of Ms. McGlynn brings the number of Vertex board members to eight.

"Ms. McGlynn will provide our Board with invaluable commercial expertise as we await the approval of INCIVEK for people with hepatitis C," said Matthew Emmens, Vertex's Chairman, President and Chief Executive Officer. "I welcome Margie to our Board and look forward to her contributions at this exciting time for our company."

Also at today's Annual Meeting, Vertex shareholders voted in favor of the compensation of Vertex's named executive officers and voted for the next advisory vote on the company's executive compensation program to be conducted next year. Shareholders also ratified the selection of Ernst & Young LLP to serve as Vertex's independent registered public accounting firm for the year ending December 31, 2011.

About Vertex

Vertex creates new possibilities in medicine. Our team aims to discover, develop and commercialize innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.

Founded more than 20 years ago in Cambridge, MA, we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada.

INCIVEKTM is a trademark of Vertex Pharmaceuticals Incorporated.

VRTX-GEN

Vertex Contacts:
Investors
Michael Partridge, 617-444-6108
or
Lora Pike, 617-444-6755
or
Matthew Osborne, 617-444-6057
or
Media
Zachry Barber, 617-444-6992
or
mediainfo@vrtx.com

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media